Filed with ASX · · 2 pages · English
Noxopharm Ltd. has issued a Cleansing Statement regarding a recent Placement of shares. The statement confirms compliance with relevant provisions of the Corporations Act and discloses that the shares were issued without prior disclosure to investors. Noxopharm assures that there is no excluded information that needs to be disclosed at this time. This announcement has been authorized by the Board of Noxopharm Limited.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Cleansing Statement Sydney, 5 November 2026: Australian clinical-stage biotechnology company Noxopharm Limited (ASX:NOX) (Noxopharm or the Company) refers to the Placement announced to ASX in the Appendix 3B dated 2 November 2026 and the Appendix 2A lodged today for the issue of 26,853,552 fully...
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm